How Bayer AG Makes Money

Pharmaceutical revenues come from prescription drug sales to healthcare providers, hospitals, and pharmacies worldwide, supplemented by license fees from partnership arrangements. License revenues from the U.S. where Johnson & Johnson subsidiary Janssen markets Xarelto, remained at prior-year levels, providing a partial buffer. The gross margin for Pharmaceuticals was approximately 74.6% in 2024 (implied from cost of goods sold of $5.0 billion on $19.8 billion sales), though this is compressed by license fee payments to partners and the product mix shift toward newer, lower-margin launches. Corn Seed & Traits showed strong growth, offsetting some glyphosate weakness, while the soybean and cotton seed businesses faced pricing pressure. The five-year framework announced in 2024 aims to improve Crop Science profitability through portfolio streamlining, cost reduction, and strategic pricing actions, but execution remains uncertain. The net result is a company where operational costs are growing faster than revenues, squeezing profitability even before litigation and special charges are considered. However, Vabysmo's dual angiopoietin-2/VEGF-A mechanism has demonstrated non-inferiority to Eylea with less frequent dosing, creating a competitive threat that Bayer must address through continued formulation innovation and pricing strategy. The competitive pattern is shaped by three factors: Chinese generic manufacturers who have captured significant glyphosate market share through lower pricing; seed trait competition where Corteva and Syngenta each have proprietary platforms; and regulatory pressure that favors biological and reduced-chemistry alternatives. Bayer's brand strength provides defense in categories where consumers prioritize trusted names (analgesics, allergy), but in commoditized categories (vitamins, basic skincare), private-label alternatives erode pricing power. The product generated license revenues in the United States at prior-year levels because Janssen (Johnson & Johnson) markets it there, but this revenue stream is also time-limited. Eylea competes with Regeneron's own aflibercept franchise and Roche's Vabysmo in ophthalmology, where the 8mg formulation provides differentiation but faces pricing pressure from biosimilar competition. The five-year framework focuses on portfolio streamlining (exiting low-margin products and geographies), cost reduction (manufacturing improvement, supply chain rationalization), and strategic pricing (value-based pricing for premium seeds and traits). The five-year framework announced in 2024 aims to improve profitability through portfolio streamlining, cost reduction, and strategic pricing. In 1903, Bayer licensed diethylbarbituric acid from Emil Fischer and Joseph von Mering, marketing it as Veronal, the first barbiturate sleep aid. The success of Aspirin demonstrated that pharmaceutical branding worked differently from dye branding: a medicine associated with a trusted company name commanded premium pricing over chemically identical generic versions, a principle that still drives pharmaceutical strategy 125 years later.

The pharmaceutical portfolio's growth products — Nubeqa for prostate cancer and Kerendia for chronic kidney disease — are growing rapidly enough to offset the decline of Xarelto, the blood thinner whose US revenue sharing arrangement with Johnson & Johnson ends when the drug loses exclusivity. The Pharmaceutical segment's growth products — Nubeqa and Kerendia — are accelerating. The pattern Shared Ownership (DSO) initiative has eliminated roughly half of all management positions, reduced hierarchy layers across the organization, and cut total headcount by over 12,000 — from 102,048 in mid-2023 to 89,556 by mid-2025. Anderson has also dismantled the pharmaceuticals leadership team, reducing it from 14 to 8 executives, and redirected R&D investment toward cell and gene therapy, chemoproteomics, and oncology. Eylea (aflibercept) ophthalmology drug maintained growth with the launch of an 8mg formulation offering longer treatment intervals. Yet these growth products must offset the collapse of Xarelto, which faces accelerating generic erosion in 2026, and the structural challenges in Crop Science, where glyphosate revenues continue declining and regulatory headwinds intensify. This valuation disconnect reflects investor skepticism about whether the litigation can be contained, whether the restructuring can deliver promised savings, and whether the pharmaceuticals pipeline can generate sufficient growth to offset Xarelto's decline. Under CEO Bill Anderson, who took office in June 2023, Bayer is executing a comprehensive transformation with five priorities: strengthening pharmaceuticals pipeline, improving Crop Science profitability, implementing the pattern Shared Ownership operating model to cut bureaucracy, deleveraging, and containing U.S. Litigation risks. The division requires heavy capital investment in R&D (seed trait development, new chemistry discovery) and manufacturing (the Soda Springs, Idaho facility for glyphosate raw materials, the Monheim R&D campus expansion). The division has pursued portfolio improvement, divesting non-core brands and focusing on high-growth categories like dermatology and digestive health, which outperformed in 2024. Kerendia's non-steroidal structure provides a differentiated safety profile with less risk of hyperkalemia, but the FDA approval for heart failure in 2025 expands the addressable market significantly. The competitive pattern is shifting toward retailer consolidation and private-label growth, particularly in the U.S. Where Amazon's private-label health products and Walmart's Equate brand capture increasing share. The conglomerate structure, once a strength (diversification across health and agriculture), is now viewed by many investors as a weakness that creates complexity, reduces strategic focus, and prevents the company from achieving the valuation multiples of pure-play pharmaceutical or agricultural peers. The financial narrative is therefore one of a company in defensive mode: managing decline in legacy products, investing in new launches, funding litigation defense, and restructuring operations — all while trying to reduce debt and preserve cash. The product mix shift within Pharmaceuticals is therefore working against margin: declining high-margin Xarelto sales are being replaced by growing but lower-margin new launches that require heavy marketing investment. Regulatory headwinds are intensifying: the European Union's Farm to Fork strategy aims to reduce chemical pesticide use by 50% by 2030, and individual member states (Germany, France) have imposed or are considering glyphosate bans. The litigation overhang is the single most consequential challenge and the primary driver of investor skepticism. The company now faces a multi-pronged strategy: managing individual cases, negotiating class action settlements, and lobbying for legislative reforms to cap punitive damages. The cell and gene therapy investments, while early-stage, position Bayer in a therapeutic modality that could transform treatment paradigms in hematology and oncology. The chemoproteomics platform, acquired through partnerships and internal development, offers a differentiated approach to drug discovery that targets previously undruggable proteins. This financial firepower enables Bayer to sustain multi-year litigation battles, fund late-stage clinical trials, and acquire complementary assets if opportunities arise. Bayer's growth strategy under CEO Bill Anderson rests on four specific, named initiatives with measurable targets: (1) driving Nubeqa and Kerendia to combined peak sales exceeding $5.5 billion by 2028-2030; (2) improving Crop Science EBITDA margins by 300-500 basis points through the five-year framework; (3) achieving $2.2 billion in annual cost savings by 2026 through pattern Shared Ownership; and (4) reducing net financial debt to below $27.3 billion to restore strategic flexibility and dividend capacity. The Nubeqa strategy is the highest-priority pharmaceutical initiative. Bayer is investing heavily in urology and oncology sales forces to capture share from Erleada and Xtandi, particularly as Xtandi approaches patent expiry. The Kerendia strategy targets the intersection of diabetes, chronic kidney disease, and heart failure — a patient population of tens of millions globally. Bayer is building a dedicated cardiovascular sales force and pursuing formulary access with Medicare and commercial payers. The Eylea strategy focuses on the 8mg formulation's extended dosing interval as a competitive differentiator against Vabysmo and biosimilars. The radiology business, while smaller, provides stable, recurring revenues with less patent cliff risk and is being expanded through new contrast agent formulations and injection systems. The Crop Science growth strategy is defensive rather than expansive. The digital agriculture platform (Climate FieldView) is being enhanced with AI-driven recommendations and expanded to emerging markets. However, the growth outlook is constrained by glyphosate structural decline and regulatory pressure. Honestly, the Consumer Health strategy focuses on portfolio improvement and geographic expansion. The division is expanding in emerging markets where OTC penetration is lower and brand recognition provides competitive advantage. The cost reduction strategy through pattern Shared Ownership is the most far-reaching initiative. The 2024 annual report notes that 'the number of management positions has been roughly halved' and 'there are now around 11,000 fewer positions overall at Bayer.' The deleveraging strategy is equally specific. The litigation strategy, while less quantifiable, includes specific tactical elements: individual case management to control verdict sizes, class action settlements to resolve large claim volumes, legislative lobbying for punitive damage caps, and scientific defense of glyphosate safety through regulatory submissions and peer-reviewed publications. The five priorities, articulated in the 2024 annual report and reinforced by the Supervisory Board's contract extension of Anderson through March 2029, are: (1) strengthening the Pharmaceuticals pipeline, (2) improving Crop Science profitability, (3) becoming leaner and more novel through pattern Shared Ownership, (4) deleveraging the balance sheet, and (5) containing U.S. Litigation risks. The FDA approval in June 2025 for metastatic castration-sensitive prostate cancer (based on the ARANOTE trial) expands the addressable patient population significantly. The ANZUP trial investigating adjuvant use in localized high-risk prostate cancer, if positive, could further extend Nubeqa's market. The litigation containment strategy is the most uncertain priority. The path to recovery depends on Nubeqa and Kerendia growth exceeding Xarelto decline, Crop Science stabilization, and litigation costs peaking and declining. If these conditions are met, Bayer could return to consistent profitability and begin rebuilding shareholder returns by 2027-2028. The company lost its American market for decades and was forced to rebuild its international presence from scratch. In 2015, Bayer spun off its materials science division as Covestro through an IPO, focusing the remaining company on life sciences.